In this regard, the expression, activity and secretion of specific S100 isoforms appear to be significantly deregulated at different stages of NAFLD/NASH and with HCC developing through an increased grade of severity. This evidence concerns the gene S100B and metabolic dysfunction-associated steatotic liver disease.